Background {#Sec1}
==========

Sulfasalazine (SSZ) is one of the disease-modifying antirheumatic drugs (DMARDs) and has been widely used for the treatment of ankylosing spondylitis (AS) in China for years \[[@CR1]\]. Though the efficacy of SSZ in treating AS is still under debate, Chinese rheumatologists prefer to prescribe SSZ for the treatment of AS because of its good cost-effectiveness ratio. Nevertheless, the therapy is often terminated in about 14--38% of AS patients receiving SSZ treatment because of adverse drug reactions (ADRs) \[[@CR2]--[@CR4]\]. There is currently no effective method of identifying a patient's susceptibility to SSZ-induced ADRs. Thus, predicting the therapeutic response of AS patients to SSZ is of great importance for individualized therapies of AS.

SSZ is constituted by 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP). SP is considered to be an active component for the therapy of AS \[[@CR5]\], and is related to ADRs such as nausea, vomiting, and headache \[[@CR6]\], while 5-ASA is effective for the treatment of inflammatory bowel disease and is related to ADRs such as diarrhea \[[@CR7]\]. When orally administered, SSZ is metabolized into SP and 5-ASA in the presence of the gut microbiota \[[@CR8], [@CR9]\]. SP is almost completely absorbed and metabolized to *N*-acetyl-SP predominantly by hepatic arylamine *N*-acetyltransferase 2 (NAT2), while only about 20--30% of 5-ASA is absorbed and metabolized to *N*-acetyl-5-ASA by arylamine *N*-acetyltransferase 1 (NAT1), the rest being eliminated in the feces \[[@CR9], [@CR10]\]. Therefore, arylamine *N*-acetyltransferases (NATs) play an important role in the metabolism of SP and 5-ASA.

Humans have two functional *NAT* genes (*NAT1* and *NAT2*) and a pseudogene (*NATP*), all found on chromosome 8p22 \[[@CR11]\]. Genetic mutations of *NAT1* and *NAT2* result in amino acid substitutions of their protein products, and may lead to altered gene expression and activity of the NAT enzyme \[[@CR11]--[@CR14]\]. These changes were shown to contribute to increased susceptibility to a range of disorders including autoimmune diseases \[[@CR15]--[@CR20]\] and carcinomas \[[@CR21]--[@CR24]\], but were also linked to the differences in the ability to *N*-acetylate certain drugs including SSZ \[[@CR6], [@CR10], [@CR25]--[@CR29]\]. In this study, we investigated the genotypes of the two human *NATs* in Han Chinese patients with AS *versus* healthy controls and also the potential correlation between *NAT* polymorphisms and SSZ-induced ADRs.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

Two hundred and sixty-six consecutive cases of AS from the First Affiliated Hospital of Shantou University Medical College were studied during the period of 2004--2010. All patients were diagnosed based on the Modified New York Criteria of AS \[[@CR30]\]. All patients were treated with SSZ at a dose of 1.5--3.0 g/day (Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd, China). Non-steroidal anti-inflammatory drugs were prescribed as needed. Two hundred and eighty healthy volunteers served as the healthy controls. All subjects were Han Chinese residing in Shantou, China. This study was approved by the Institutional Ethics Committee of Shantou University Medical College, and written informed consent was obtained from all participants.

Determination of *NAT*genetic polymorphisms {#Sec4}
-------------------------------------------

Genomic DNA was extracted from peripheral blood samples with the QIAamp Blood Kit (QIAGEN, Hilden, Germany) and stored at -80°C. Genetic polymorphisms of *NAT1* (*NAT1\*4*, *NAT1\*3*, *NAT1\*10*, *NAT1\*11*) and *NAT2* (*NAT2\*4*, *NAT2\*5*, *NAT2\*6*, *NAT2\*7*) were determined using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method \[[@CR24], [@CR31]\]. The *NAT* genotypes of a number of samples were confirmed through direct DNA sequencing for quality control purposes. Subjects were classified as *NAT1* fast acetylator genotype carriers (those with at least one *NAT1\*10* allele) or *NAT1* slow acetylator genotype carriers (those without *NAT1\*10* allele) \[[@CR24]\]. Individuals carrying at least one wild-type allele (*NAT2\*4* allele) were classified as *NAT2* fast acetylator genotype carrier, and those carrying the mutant allele (*NAT2\*5*, *\*6*, *\*7*) were classified as *NAT2* slow acetylator genotype carriers \[[@CR32]\].

Observation of clinical features {#Sec5}
--------------------------------

Clinical features observed included age of onset, duration of disease, joint involvement (classified into two types: axial joint involvement only, and both axial and peripheral joint involvements), incidence of radiological hip involvement, and HLA-B27 status.

Assessment of ADRs {#Sec6}
------------------

All patients were followed up for more than 2 years and SSZ-induced ADRs were monitored. ADRs and severe ADRs were defined according to the criteria proposed by Edwards et al. \[[@CR33]\]. ADRs were classified into six types: dose-related (Augmented), non-dose-related (Bizarre), dose-related and time-related (Chronic), time-related (Delayed), withdrawal (End of use), and failure of therapy (Failure). The causality assessment of suspected ADRs was determined as described previously \[[@CR33]\]. ADRs were classified as being "certain", "probable", "possible", "unlikely", "conditional", and "unassessable". All ADRs noted in this study were "certain", "probable", or "possible".

Statistical analysis {#Sec7}
--------------------

Data were analyzed using SPSS 19.0 statistical software. Departure from the Hardy--Weinberg equilibrium was tested by the chi-squared test. Frequencies of the alleles, genotypes, acetylator genotypes, and co-occurrence of *NAT1* with *NAT2* acetylator genotypes in each group were compared using chi-squared test or the Fisher's exact test as appropriate. Age of onset and duration of disease in each group were compared using t-test, one-way ANOVA test or Kruskal Wallis test as appropriate. Odds ratio (OR) and a 95% confidence interval (95% CI) were estimated from logistic regression models to test for associations between the risk of SSZ-induced ADRs and the *NAT* acetylator genotypes. Binary logistic regression analysis was used to identify the variables (*NAT* acetylator genotype, dose, age, sex, and NSAIDs combination) that provided an important contribution towards the variability of SSZ-induced ADRs and to adjust for confounding variables by analysis of covariates. The prevalence of drug treatment termination because of SSZ-induced ADRs in each group was compared using the chi-squared test or the Fisher's exact test as appropriate. Differences in the duration of ADRs occurring in each group were compared using the Mann--Whitney U test. *P* \< 0.05 was considered statistically significant.

Results {#Sec8}
=======

Subject characteristics {#Sec9}
-----------------------

Of the AS patients, 219 were male and 47 were female. The positive rate of HLA-B27 in patients was 90.2%. The mean age was 27.8 ± 9.1 years and the mean disease duration was 6.8 ± 5.7 years. The control group included 221 male and 59 female healthy volunteers with a mean age of 35.1 ± 10.0 years.

*NAT*polymorphisms in AS patients and healthy controls {#Sec10}
------------------------------------------------------

The distribution of *NAT1* and *NAT2* gene polymorphisms in AS patients and healthy controls is shown in Table [1](#Tab1){ref-type="table"}. The allele frequencies of both AS patients and healthy controls were consistent with the Hardy--Weinberg equilibrium (*P* \> 0.05). No significant differences between the AS and control group were found for the distribution of alleles, genotypes, and acetylator genotypes when *NAT1* and *NAT2* polymorphisms were analyzed independently. However, the co-occurrence frequency of the *NAT2* fast acetylator genotype and *NAT1\*10*/*NAT1\*10* genotype was lower in AS patients than in controls (6.4% *vs* 11.4%, *P* = 0.04, OR = 0.53, 95% CI 0.29--0.98).Table 1**Distribution of** ***NAT*** **polymorphisms in AS patients and healthy controls**Alleles/Genotypes/Acetylator genotypesASHCχ ^2^***P***N%N%*NAT1* Alleles*NAT1\*4*26850.426146.61.550.21*NAT1\*3*10119.010819.30.020.90*NAT1\*10*15929.918833.61.710.19*NAT1\*11*40.730.5-0.72\*Total532560*NAT1* Genotypes*NAT1\*4/NAT1\*4*7528.26523.21.780.18*NAT1\*4/NAT1\*3*3914.74817.10.630.43*NAT1\*4/NAT1\*10*7728.98028.60.010.92*NAT1\*4/NAT1\*11*20.831.1-1.00\**NAT1\*3/NAT1\*3*145.2145.00.020.89*NAT1\*3/NAT1\*10*3412.83211.40.240.63*NAT1\*3/ NAT1\*11*0000\--*NAT1\*10/NAT1\*10*238.63813.63.330.07*NAT1\*10/NAT1\*11*20.800\--*NAT1\*11/NAT1\*11*0000\--Total266280*NAT1* Acetylator GenotypesFast13651.115053.60.330.57Slow13048.913046.4Total266280*NAT2* Alleles*NAT2\*4*31058.334060.70.680.41*NAT2\*5*183.4183.20.020.88*NAT2\*6*13425.212923.00.690.41*NAT2\*7*7013.17313.10.000.95Total532560*NAT2* Genotypes*NAT2\*4/NAT2\*4*9836.811039.30.350.56*NAT2\*4/NAT2\*5*93.4103.60.010.91*NAT2\*4/NAT2\*6*7026.37125.40.070.80*NAT2\*4/NAT2\*7*3513.23913.90.070.79*NAT2\*5/NAT2\*5*0010.4\--*NAT2\*5/NAT2\*6*62.320.7-0.17\**NAT2\*5/NAT2\*7*31.141.4-1.00\**NAT2\*6/NAT2\*6*186.8186.40.030.87*NAT2\*6/NAT2\*7*228.2207.10.240.62*NAT2\*7/NAT2\*7*51.951.8-1.00\*Total266280*NAT2* Acetylator GenotypesFast21279.723082.10.530.47Slow5420.35017.9Total266280*NAT2* fast acetylator genotype plus *NAT1\*10*/*NAT1\*10*176.43211.44.240.04\*Results of Fisher's exact test; AS = Ankylosing Spondylitis; HC = healthy control; *NAT1* = Arylamine *N*-acetyltransferases 1; *NAT2* = Arylamine *N*-acetyltransferases 2; N = Number; χ^2^ = Chi-squared test.

Correlations between *NAT*polymorphisms and clinical features of AS {#Sec11}
-------------------------------------------------------------------

The age of onset, duration of disease, joint involvement types, incidence of radiological hip involvement, and the positive rate of HLA-B27 were not significantly different in each *NAT* genotype or *NAT* acetylator genotype group among the AS patients (*P* \> 0.05).

SSZ-induced ADRs {#Sec12}
----------------

SSZ-induced ADRs occurred in 25 cases (9.4%) of AS (Table [2](#Tab2){ref-type="table"}). Among these, 16 patients (64.0%) experienced dose-related ADRs; eight patients (32.0%) experienced non-dose-related ADRs, and one patient (4.0%) experienced time-related ADR. The dose-related ADRs observed in this study included nausea, anorexia, abdominal pain, diarrhea, epigastric discomfort, dizziness, elevation of serum liver enzyme levels, and chest congestion. Non-dose-related ADRs included rash, oral ulcer, and leukopenia. One patient with cacospermia was classified as having time-related ADR. No serious ADRs were found in the AS group of patients. SSZ therapy was terminated because of SSZ-induced ADRs in 19 AS patients (7.1%). Of these, 10 patients (52.6%) withdrew from SSZ therapy because of dose-related ADRs; eight patients (42.1%) because of non-dose-related ADRs, and one patient (5.3%) because of time-related ADR. The mean duration of SSZ therapy from the time when the first ADR occurred was 19 days (range 3--450 days). Most ADRs occurred within 12 weeks after the start of SSZ treatment (23 cases, 92.0%).Table 2**Clinical features and** ***NAT*** **polymorphisms in 25 AS patients who experienced SSZ-induced ADRs**ADR types\*CasesSSZ Dose (g/day)ADRTermination of Drug therapy***NAT2**NAT1***GenotypesAcetylator\
genotypesGenotypesAcetylator\
genotypes**Dose-related**Case 13.0NauseaNo*NAT2\*4/NAT2\*7*Fast*NAT1\*10/NAT1\*10*FastCase 23.0Nausea, anorexiaNo*NAT2\*4/NAT2\*5*Fast*NAT1\*3/NAT1\*10*FastCase 31.5Abdominal painYes*NAT2\*4/NAT2\*6*Fast*NAT1\*4/NAT1\*10*FastCase 43.0DiarrheaYes*NAT2\*7/NAT2\*7*Slow*NAT1\*4/NAT1\*4*SlowCase 53.0DiarrheaNo*NAT2\*5/NAT2\*7*Slow*NAT1\*4/NAT1\*4*SlowCase 63.0Epigastric discomfortNo*NAT2\*4/NAT2\*4*Fast*NAT1\*4/NAT1\*10*FastCase 71.5Epigastric discomfortYes*NAT2\*4/NAT2\*7*Fast*NAT1\*4/NAT1\*10*FastCase 81.5Increase in transaminasesYes*NAT2\*6/NAT2\*7*Slow*NAT1\*4/NAT1\*4*SlowCase 9\#2.25Increase in transaminasesYes*NAT2\*6/NAT2\*7*Slow*NAT1\*4/NAT1\*3*SlowCase 102.25DizzinessNo*NAT2\*6/NAT2\*7*Slow*NAT1\*3/NAT1\*3*SlowCase 111.5DizzinessYes*NAT2\*6/NAT2\*6*Slow*NAT1\*4/NAT1\*4*SlowCase 121.5DizzinessYes*NAT2\*5/NAT2\*6*Slow*NAT1\*4/NAT1\*4*SlowCase 131.5DizzinessYes*NAT2\*4/NAT2\*7*Fast*NAT1\*10/NAT1\*10*FastCase 141.5DizzinessYes*NAT2\*6/NAT2\*6*Slow*NAT1\*4/NAT1\*4*SlowCase 153.0DizzinessNo*NAT2\*4/NAT2\*4*Fast*NAT1\*4/NAT1\*4*SlowCase 161.5Chest congestionYes*NAT2\*5/NAT2\*6*Slow*NAT1\*4/NAT1\*3*Slow**Non-dose-related**Case 172.25LeukopeniaYes*NAT2\*4/NAT2\*6*Fast*NAT1\*4/NAT1\*4*SlowCase 181.5RashYes*NAT2\*6/NAT2\*6*Slow*NAT1\*4/NAT1\*4*SlowCase 191.5RashYes*NAT2\*4/NAT2\*6*Fast*NAT1\*3/NAT1\*10*FastCase 201.5RashYes*NAT2\*4/NAT2\*6*Fast*NAT1\*4/NAT1\*11*SlowCase 213.0RashYes*NAT2\*4/NAT2\*4*Fast*NAT1\*4/NAT1\*10*FastCase 223.0RashYes*NAT2\*4/NAT2\*4*Fast*NAT1\*3/NAT1\*10*FastCase 232.25Oral ulcerYes*NAT2\*4/NAT2\*4*Fast*NAT1\*10/NAT1\*10*FastCase 242.25Oral ulcerYes*NAT2\*4/NAT2\*4*Fast*NAT1\*4/NAT1\*10*Fast**Time-related**Case 25\#2.25CacospermiaYes*NAT2\*4/NAT2\*6*Fast*NAT1\*3/NAT1\*3*Slow\*ADRs were classified into six types: dose-related, non-dose-related, dose-related and time-related, time-related, withdrawal (End of use), and failure of therapy; \#Case 9 was observed to have elevated serum liver enzyme levels at day 138 and case 25 had cacospermia at day 450 after the start of SSZ treatment; ADRs = Adverse Drug Reactions; *NAT1* = Arylamine *N*-acetyltransferases 1; *NAT2* = Arylamine *N*-acetyltransferases 2; SSZ = Sulfasalazine.

Correlations of *NAT*polymorphisms and SSZ-induced ADRs {#Sec13}
-------------------------------------------------------

Correlations between *NAT* acetylator genotypes and SSZ-induced ADRs are shown in Table [3](#Tab3){ref-type="table"}. The incidence of overall ADRs in patients carrying the *NAT2* slow acetylator genotype was 18.5% (10/54) and was significantly higher than patients carrying the *NAT2* fast acetylator genotype (7.1%, 15/212, *P* = 0.013, OR = 2.99, 95% CI 1.26---7.09). The incidence of dose-related ADRs in patients carrying the *NAT2* slow acetylator genotype was also higher than in patients carrying the fast acetylator genotype (16.7% *vs* 3.3%, *P* = 0.002, OR = 5.17, 95% CI 1.79---14.92). No significant difference in the incidence of non-dose-related ADRs was found between the *NAT2* fast and *NAT2* slow acetylator genotype groups (3.3% *vs* 1.9%, *P* \> 0.05). The prevalence of drug treatment termination owing to ADRs or dose-related ADRs was higher in the *NAT2* slow acetylator genotype carriers than in the fast-type carriers (14.8% *vs* 5.2%, *P* = 0.032 and 13.0% *vs* 1.4%, *P* = 0.001, respectively).Table 3**Associations between** ***NAT*** **acetylator genotypes and SSZ-induced ADRs*NAT2***acetylator genotype***NAT1***acetylator genotypeCo-existence of ***NAT1***and ***NAT2***acetylator genotypesFastSlowFastSlow***NAT1***slow plus ***NAT2***slowNon ***NAT1***slow plus ***NAT2***slowTotal ADRs7.1%(15/212)18.5%(10/54)8.1%(11/136)10.8%(14/130)26.3%(10/38)6.6%(15/228)*P*\*0.0130.45\<0.001OR\*2.995.0795% CI\*1.26-7.092.08-12.37Drug therapy termination rate due to ADRs5.2%(11/212)14.8%(8/54)5.9%(8/136)8.5%(11/130)21.1%(8/38)4.8%(11/228)*P*0.032\#0.410.002\#Dose-related ADR3.3%(7/212)16.7%(9/54)4.4%(6/136)7.7%(10/130)23.7%(9/38)3.1%(7/228)*P*\*0.0020.27\<0.001OR\*5.179.5295% CI\*1.79-14.923.20-28.30Drug therapy termination rate due to dose-related ADRs1.4%(3/212)13.0%(7/54)2.2%(3/136)5.4%(7/130)18.4%(7/38)1.3%(3/228)*P*0.001\#0.21\#\<0.001\#Non-dose-related ADR3.3%(7/212)1.8%(1/54)3.7%(5/136)2.3%(3/130)2.6%(1/38)3.1%(7/228)*P*\*0.580.510.88\*Results of binary logistic regression analysis after adjusting for dose, age, sex, and NSAIDs combination; \#Results of Fisher's exact test; OR = odds ratio; CI = confidence interval; ADRs = Adverse Drug Reactions; *NAT1* = Arylamine *N*-acetyltransferases 1; *NAT2* = Arylamine *N*-acetyltransferases 2; SSZ = Sulfasalazine.

The incidences of overall ADRs, dose-related ADRs, and non-dose-related ADRs in patients carrying the *NAT1* fast acetylator genotype were 8.1% (11/136), 4.4% (6/136), and 3.7% (5/136) respectively, similar to 10.8% (14/130), 7.7% (10/130), and 2.3% (3/130) in patients carrying the *NAT1* slow acetylator genotype (*P* \> 0.05). The prevalence of drug treatment termination owing to overall ADRs or dose-related ADRs was slightly higher in the *NAT1* slow acetylator genotype carriers than in the fast-type carriers (8.5% *vs* 5.9%, and 5.4% *vs* 2.2%, respectively). However, the difference was not significant (*P* \> 0.05).

The incidences of both overall ADRs and dose-related ADRs were higher in patients carrying both the *NAT1* slow acetylator genotype and the *NAT2* slow acetylator genotype than in the other carriers (26.3% *vs* 6.6%, *P* \< 0.001, OR = 5.07, 95% CI 2.08--12.37 and 23.7% *vs* 3.1%, *P* \< 0.001, OR = 9.52, 95% CI 3.20--28.30). The prevalence of drug treatment termination owing to overall ADRs or dose-related ADRs was also higher in the carriers of both *NAT1* slow acetylator genotype and *NAT2* slow acetylator genotype than in the other carriers (21.1% *vs* 4.8%, *P* = 0.002 and 18.4% *vs* 1.3%, *P* \< 0.001, respectively). The mean duration of SSZ treatment when the first ADR occurred in patients carrying both the *NAT1* slow acetylator genotype and the *NAT2* slow acetylator genotypes was 8 days (range 3--128 days), shorter than that of 33 days (range 10--450 days) in the carriers of other acetylator genotypes (*P* = 0.003). No significant differences in the frequencies of non-dose-related ADRs were found among carriers of any *NAT1* and *NAT2* acetylator genotype combinations (*P* \> 0.05).

Only one patient was identified that experienced time-related ADR and carried *NAT1* slow acetylator (*NAT1\*3/NAT1\*3*) and *NAT2* fast acetylator (*NAT2\*4/NAT*2\*6) genotypes.

Discussion {#Sec14}
==========

This study showed that the *NAT* genotype appeared not to correlate with the development of AS or the clinical features of AS such as age of onset, duration of disease, joint involvements, incidence of radiological hip involvement, or positive status of HLA-B27. However, the frequency of co-occurrence of the *NAT2* fast acetylator genotype and the *NAT1\*10*/*NAT1\*10* genotype was significantly lower in AS patients than in healthy controls (*P* = 0.04, OR = 0.53, 95% CI 0.29--0.98). This suggests that the co-occurrence of the *NAT2* fast acetylator genotype and the *NAT1\*10*/*NAT1\*10* genotype is likely to reduce one-half the risk of AS in the Chinese Han population. It was reported that partial linkage disequilibrium exists between the *NAT1\*10* allele and the *NAT2* fast acetylation genotype, and a reduced risk for bladder cancer was identified in carriers of these co-existing genotypes \[[@CR34]\]. Because the sample size of our study was relatively small, further investigation should be conducted to reveal the biological significance of the partial linkage disequilibrium between the *NAT1\*10* allele and the *NAT2* fast acetylation genotype in the development of AS.

In the current study, the most common SSZ-induced ADR were gastrointestinal reactions (nausea and diarrhea), followed by rash, dizziness, and elevated levels of serum liver transaminases. Hematological disturbances (leukopenia) and cacospermia were rarely seen. These characteristics were similar to those reported in previous studies \[[@CR9], [@CR35]\]. It was also reported that most SSZ-induced ADRs occurred within the first 12 weeks of SSZ treatment \[[@CR36]\]. In our study, most ADRs (92%) also occurred within the first 12 weeks. However, one patient (case 9) was observed to have elevated serum liver enzyme levels at day 138 and another patient (case 25) had cacospermia at day 450 after the start of SSZ treatment. This indicates it is important to monitor the ADRs during the first 12 weeks of SSZ treatment. However, liver function tests need to be carried out beyond 12 weeks. Morphological examination and motility tests for sperm are also important for male patients.

The association between single nucleotide polymorphisms (SNPs) and *NAT* expression has been described in previous reports \[[@CR11]--[@CR14]\]. For example, 341 T \> C (I114T) and 590G \> A (R197Q) reduce NAT2 catalytic activities, whereas 481C \> T (L161L) do not. *NAT* polymorphisms linked to the differences in the ability to *N*-acetylate SSZ have been identified \[[@CR6], [@CR10], [@CR25]--[@CR29]\]. However, it is still not clear whether the genetic variants of *NAT1* and *NAT2* underlie the patients' response to SSZ. Previous studies identified a strong association between *NAT2* polymorphisms and SSZ-induced ADRs \[[@CR20], [@CR31], [@CR37]--[@CR39]\] and this association was thought to have an effect on the efficacy of SSZ \[[@CR26], [@CR39]\] . However, others suggested that *NAT1* and *NAT2* polymorphisms played no roles in predicting responses to SSZ or related toxicities \[[@CR40], [@CR41]\]. In our study, the frequencies of overall ADRs and dose-related ADRs of SSZ were higher in the *NAT2* slow acetylation genotype group than in the *NAT2* fast-type group. The ORs were 2.99 (95% CI 1.26--7.09) and 5.17 (95% CI 1.79--14.92), respectively, indicating that the *NAT2* slow acetylator genotype may be a risk factor for ADRs, especially the dose-related ADRs of SSZ. In addition, the prevalence of SSZ treatment terminations owing to overall ADRs or dose-related ADRs was also higher in the *NAT2* slow acetylator genotype carriers as compared with that in the *NAT2* fast-type carriers (14.8% *vs* 5.2%, *P* = 0.032 and 13.0% vs 1.4%, *P* = 0.001). In our study, non-dose-related ADRs only occurred in one patient carrying the *NAT2* slow acetylator genotype. Therefore, it is difficult to evaluate the contribution of the *NAT2* acetylation genotype to non-dose-related ADRs of SSZ.

The NAT1 function is also widely variable in human populations, although the effects of its genetic polymorphisms are not generally as marked as those of NAT2 \[[@CR12], [@CR13], [@CR42]\]. The current study provided little evidence of correlation between *NAT1* acetylator genotypes and the risk of SSZ-induced ADRs by *NAT1* single-gene analysis. However, the co-existence of the *NAT1* slow acetylator genotype and the *NAT2* slow acetylator genotype conferred a 5-fold greater risk for overall ADRs, and a 9-fold greater risk for dose-related ADRs as compared with other acetylator genotype carriers. The termination of SSZ treatment owing to overall ADRs or dose-related ADRs was more commonly seen in AS patients carrying the *NAT1* slow and *NAT2* slow acetylator genotypes. Additionally, the onset of ADRs was earlier in patients with co-existing the *NAT1* slow and *NAT2* slow acetylator genotypes than that for other acetylator genotype carriers (8 *vs* 33 days, *P* = 0.003). These findings allow the identification of patients at a possible risk of SSZ-induced ADRs or subsequent terminations of SSZ treatment. It is also important to note that a multi-gene analysis approach is still worthwhile in pharmacogenetic studies even if no positive correlations are found *via* a single gene analysis.

Similar to the findings of other studies involving Asians such as Chinese and Japanese populations \[[@CR19], [@CR43]\], our results showed the prevalence of the *NAT2* slow acetylator genotype was 20.3% in Han Chinese patients with AS, which is significantly lower than that reported for Western populations (40--70%) \[[@CR13]\]. This might explain why SSZ-induced ADRs are much less prevalent among the Chinese (9.4% in our study population) and the Japanese (11.1%) \[[@CR37]\] as compared with Western populations (22.7-53.5%) \[[@CR2], [@CR9], [@CR35], [@CR40]\]. However, the statistical power is relatively low because of the low frequency of the *NAT2* slow acetylator genotype in our study population. It is a challenge to evaluate correlations between *NAT* polymorphisms and SSZ-induced ADRs without bias. Thus, studies of multi-ethnicity and larger populations are required.

Conclusions {#Sec15}
===========

The co-occurrence of the *NAT2* fast acetylator genotype and the *NAT1\*10/NAT1\*10* genotype is less frequent in AS patients compared with healthy controls in the Han Chinese population*.* The *NAT2* slow acetylator genotype and co-existing *NAT1* and *NAT2* slow acetylator genotypes appear to be associated with higher risks of SSZ-induced ADRs.
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